Clinical trials of MRS methods

Margarida Julia-Sape*, Fernando Arias-Mendoza, John R. Griffiths

*Autor corresponent d’aquest treball

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

2 Cites (Scopus)

Resum

© 2015 John Wiley & Sons, Ltd. In order to determine the applicability of noninvasive magnetic resonance spectroscopy (MRS) to the study of a diseased tissue or organ in the human body, it is necessary to determine if MRS is safe and effective. This is usually the primary purpose of a clinical trial of a novel method. A clinical trial for MRS may also reveal which technical approach works best for the specific application and characteristics of the population being studied. In this article, we discuss the legal, ethical, and scientific requirements to be considered before the start of a clinical trial of an MRS protocol, as well as constraints that may arise during its execution. MRS-specific issues arising from a couple of successful clinical MRS trials for classifying brain tumors with 1H MRS (INTERPRET and eTUMOUR) and body tumors with 31P MRS (the Cooperative Group on MRS Application in Cancer, CoGMAC) serve as illustrative examples.
Idioma originalAnglès
Pàgines (de-a)779-788
Nombre de pàgines10
RevistaeMagRes
Volum4
Número4
DOIs
Estat de la publicacióPublicada - 1 de gen. 2015

Fingerprint

Navegar pels temes de recerca de 'Clinical trials of MRS methods'. Junts formen un fingerprint únic.

Com citar-ho